ES2693165T3 - Formas monoméricas y diméricas de fragmentos de receptores de adiponectina y métodos de uso - Google Patents

Formas monoméricas y diméricas de fragmentos de receptores de adiponectina y métodos de uso Download PDF

Info

Publication number
ES2693165T3
ES2693165T3 ES10767527.4T ES10767527T ES2693165T3 ES 2693165 T3 ES2693165 T3 ES 2693165T3 ES 10767527 T ES10767527 T ES 10767527T ES 2693165 T3 ES2693165 T3 ES 2693165T3
Authority
ES
Spain
Prior art keywords
mer unit
seq
identity
unit
mer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10767527.4T
Other languages
English (en)
Spanish (es)
Inventor
Michael J. Pugia
Rui Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Inc
Original Assignee
Siemens Healthcare Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics Inc filed Critical Siemens Healthcare Diagnostics Inc
Application granted granted Critical
Publication of ES2693165T3 publication Critical patent/ES2693165T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
ES10767527.4T 2009-04-23 2010-04-13 Formas monoméricas y diméricas de fragmentos de receptores de adiponectina y métodos de uso Active ES2693165T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US171979P 1999-12-23
US17197909P 2009-04-23 2009-04-23
PCT/US2010/030836 WO2010123720A1 (en) 2009-04-23 2010-04-13 Monomeric and dimeric forms of adiponectin receptor fragments and methods of use

Publications (1)

Publication Number Publication Date
ES2693165T3 true ES2693165T3 (es) 2018-12-07

Family

ID=43011406

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10767527.4T Active ES2693165T3 (es) 2009-04-23 2010-04-13 Formas monoméricas y diméricas de fragmentos de receptores de adiponectina y métodos de uso

Country Status (6)

Country Link
US (3) US8865648B2 (https=)
EP (2) EP3444611A1 (https=)
JP (2) JP5882196B2 (https=)
CN (1) CN102388308B (https=)
ES (1) ES2693165T3 (https=)
WO (1) WO2010123720A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010123720A1 (en) 2009-04-23 2010-10-28 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
CA2735578C (en) 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EP2391377A2 (en) 2009-02-02 2011-12-07 Ramot at Tel-Aviv University Ltd. Peptides, pharmaceutical compositions comprising same and uses thereof
WO2012017439A2 (en) * 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
EA201391017A1 (ru) 2011-01-10 2014-04-30 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
JP2014517911A (ja) * 2011-04-11 2014-07-24 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッド アディポネクチン受容体ｃ末端フラグメント（ｃｔｆ）免疫グロブリン
SG11201401422VA (en) * 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
DE102015201100B4 (de) * 2015-01-22 2018-05-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Antivirale Mittel

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US20020173474A1 (en) 1993-02-12 2002-11-21 President And Fellows Of Harvard College Methods & materials involving dimerization-mediated regulation of biological events
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
JP3538711B2 (ja) 1997-10-29 2004-06-14 大塚製薬株式会社 平滑筋増殖抑制組成物、動脈硬化症診断方法及びそのキット
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
US20040067490A1 (en) 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2382015A1 (en) 1999-08-17 2001-02-22 Incyte Genomics, Inc. Membrane associated proteins
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020102617A1 (en) 2000-08-03 2002-08-01 Macbeath Gavin Protein microarrays
EP1379554A2 (en) 2001-02-21 2004-01-14 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
US20020132773A1 (en) 2001-03-14 2002-09-19 Oklahoma Medical Research Foundation Methods for reducing fat by administration of adiponectin
US20030083261A1 (en) 2001-04-30 2003-05-01 Hongtao Yu Class of 12mer peptides that inhibit the function of the mitotic check point protein Mad2
DK1426764T3 (da) 2001-08-17 2011-06-27 Fujirebio Kk Fremgangsmåde til diagnosticering eller monitorering af fejl i sukkermetabolisme
WO2004022596A1 (en) 2002-09-05 2004-03-18 Komed Co., Ltd. Monoclonal antibody against adiponectin, preparation method and use thereof
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
JP4347874B2 (ja) * 2002-12-29 2009-10-21 株式会社東京大学Ｔｌｏ アディポネクチン受容体及びそれをコードする遺伝子
EP2141235B1 (en) 2002-12-29 2014-06-11 Toudai Tlo, Ltd. Adiponectin receptor and gene coding for the same
WO2004063711A2 (en) 2003-01-09 2004-07-29 Beth Israel Deaconess Medical Center, Inc. Use of adiponectin to diagnose and treat malignancy
EP1607742B1 (en) 2003-03-24 2011-11-23 Mitsubishi Chemical Medience Corporation Latex reagent for adiponectin analysis and method of adiponectin analysis
JP4717810B2 (ja) 2003-06-20 2011-07-06 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド １型糖尿病と２型糖尿病を識別するためのバイオマーカー
US7435808B2 (en) * 2003-06-25 2008-10-14 Bristol-Myers Squibb Company Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2
ES2347562T3 (es) 2003-09-27 2010-11-02 Siemens Healthcare Diagnostics Inc. Disagnosticos y terapias para enfermedades asociados con receptor emparejado de proteina g adipor1 (adipor1).
JP2007506950A (ja) 2003-09-27 2007-03-22 バイエル・ヘルスケア・エルエルシー Ｇタンパク質共役受容体ＡｄｉｐｏＲ２（ＡｄｉｐｏＲ２）に関連する疾患の診断および治療
JP4677545B2 (ja) 2003-10-15 2011-04-27 積水メディカル株式会社 多量体アディポネクチンの分別測定方法
EP1684807B1 (en) 2003-11-07 2009-09-02 Merck & Co., Inc. Method of identifying responders to treatment with insulin sensitizers
JPWO2005084697A1 (ja) * 2004-03-04 2007-11-29 門脇　孝 アディポネクチン受容体発現制御剤
GB0426798D0 (en) 2004-12-07 2005-01-12 Emtelle Uk Ltd Optical fibre tube and method of manufacturing same
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
CN101932728B (zh) * 2007-11-30 2013-06-19 西门子医疗保健诊断公司 脂连蛋白受体片段和使用方法
WO2010123720A1 (en) 2009-04-23 2010-10-28 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use

Also Published As

Publication number Publication date
WO2010123720A1 (en) 2010-10-28
US20180346540A1 (en) 2018-12-06
JP2012524902A (ja) 2012-10-18
CN102388308B (zh) 2015-08-19
JP5882196B2 (ja) 2016-03-09
US20150038426A1 (en) 2015-02-05
EP2422199B1 (en) 2018-07-25
EP2422199A1 (en) 2012-02-29
CN102388308A (zh) 2012-03-21
JP2016035470A (ja) 2016-03-17
EP2422199A4 (en) 2013-01-30
EP3444611A1 (en) 2019-02-20
US8865648B2 (en) 2014-10-21
US20120135916A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
ES2693165T3 (es) Formas monoméricas y diméricas de fragmentos de receptores de adiponectina y métodos de uso
JP7543290B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
US8158128B2 (en) Monoclonal antibodies to progastrin
US8710180B2 (en) VEGF-specific capture agents, compositions, and methods of using and making
KR102404285B1 (ko) 생물학적 샘플에서 개선된 성능을 갖는 igfbp7에 대한 분석
KR20110000548A (ko) 신장암의 진단 또는 검출을 위한 조성물 및 방법
WO2015048929A1 (en) Biomarkers for breast cancer
JP4339564B2 (ja) 抗体およびその用途
CN102869989B (zh) 通过对随机序列聚合物的组合物基于血清蛋白的检测，改进含随机序列聚合物的组合物的设计、生物利用度和效能的方法
EA049305B1 (ru) Антитела к trem2 и способы их применения
WO2005063335A2 (en) MONOCLONAL DES-LYS58-β2-MICROGLOBULIN ANTIBODIES FOR MEASUREMENT AND MANAGEMENT OF HEMODIALYSIS COMPLICATIONS
JP2004275186A (ja) 抗体およびその用途
JP2004159654A (ja) 抗体およびその用途